-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/autism_disposition-comments.pdf
November 01, 2010 - General As discussed above, the report needs significant
editing to increase clarity and usability. … We focused the introductory section of the report on those
interventions discussed in later chapters … Reasons for the decision are not
discussed in Chapter 2. … Precision is not discussed at all. … The authors
have clearly and adequately discussed the
articles.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/childhood-cancer-disposition-comments.pdf
February 16, 2022 - We
reviewed and discussed these points
again. … Reviewer #4 Discussion
and
Conclusions
Implications of discussions are adequate and limitations are
discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/cer-244-safety-of-vaccines.pdf
May 25, 2021 - Peer Reviewer
#2
General Second, individual vaccines are
discussed in separate sections
throughout … clearly explicated in the report,
and likely pose some methodologic
limitations that should be clearly
discussed … We appreciate this suggestion and
discussed it. … Another limitation that could
have been discussed in more detail is
that all immunizations may not … detail; however,
the basis of the relative risk (including
individual study contributions) is fully
discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/binge-eating-disposition-160504.pdf
December 09, 2015 - We have
also now more explicitly discussed the IPT results and
highlighted their sustainability over … IPT and DBT are discussed earlier in the
chapter. … As discussed in this review, I am extremely concerned that
the conclusions from this report cannot be
-
effectivehealthcare.ahrq.gov/sites/default/files/innovations_in_stakeholder_engagement_conference_summary2.pdf
October 01, 2011 - These are discussed in the next section.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/progestogens-preterm-birth-disposition-121205.pdf
September 07, 2012 - With regard to safety we have updated the
report as discussed above. … This matter needs to
be considered and discussed.
See tables 4 through 16 for examples. … the Meis
trial meaning that analyses that build from the
same population are noted, counted and
discussed … And, if 2 other trials (one fair, one good) are included
in the analysis (as discussed on page 42), … considered by some to be a symptom
of preterm labor, she inquired whether the Fonseca 2007 trial
can be discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/weight-gain-prevention_disposition-comments.pdf
March 25, 2013 - The subgroups were discussed with the Key Informants and
Technical Expert Panel. … Team discussed terminology to be applied were relevant
throughout report. … As discussed above (see Introduction), the
outcome (long-term weight gain) and relevant
interventions … In considering the utility and applicability of this report,
the bar for “high” evidence should be discussed … Peer reviewer
6
Introduction Given that these topics were discussed in later sections
of the report
-
effectivehealthcare.ahrq.gov/sites/default/files/renal-cancer_disposition-comments.pdf
February 24, 2016 - This is
discussed in Research Gaps, KQ1. … A problem
we face with this literature and discussed in the
report is that numerous studies do not … perhaps state a statistically significant
association, regardless of the magnitude of
difference) are discussed … The main issue is that of verification bias. if
you believe this should be discussed here, also consider … A problem we
face with this literature and discussed in the report
is that numerous studies do not
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-274-tethered-spinal-cord-disposition-comments.pdf
October 25, 2024 - Disposition of Comments_Comparative Effectiveness Review No. 274: Diagnosis and Treatment of Tethered Spinal Cord
Comparative Effectiveness Review Disposition of Comments Report
Title: Diagnosis and Treatment of Tethered Spinal Cord
Draft report available for public comment from February 23, 2024, to…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/disparities-quality-improvement_disposition-comments.pdf
August 27, 2012 - KEY QUESTIONS: They seem reasonable, however, I
don’t see that they necessarily imply the approach
discussed … Table 2 is a very helpful distillation of the
inclusion criteria as discussed in the Analytic Framework … This
should be discussed in the text as well as in the
appropriate appendix. … I know we discussed how we were defining "health
outcomes" during one of the TEP meetings. … I know this point is
discussed later in the report (e.g. pg ES-5 lines 7-32) but
it needs to be underscored
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-222-health-equity-preventive-services-comments.pdf
December 03, 2019 - This point is discussed in the Future Research Needs
section of the report.
-
effectivehealthcare.ahrq.gov/sites/default/files/home-based-care_disposition-comments.pdf
February 16, 2016 - Costs of the intervention are not discussed -- perhaps they
are not reported by the research.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-risk-assessment-genes_disposition-comments.pdf
July 03, 2012 - Disposition of Comments Report for Multigene Panels in Prostate Cancer Risk Assessment
Source: http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-
reports/?pageaction=displayproduct&productID=1171
Published Online: July 3, 2012
Comparative Effectiveness Research Review Disposition of Comme…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/delirium-disposition-comments.pdf
September 03, 2019 - Synthesis section that outcome
definition was a key variable for determining
homogeneity and that we had discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-quantitative-synthesis_methods.pdf
October 01, 2010 - None of the authors has a financial interest in any of the products discussed in this document. … Results
We first discussed considerations for deciding whether to combine studies, followed by
discussions … Therefore, we recommend
random effects models, with exceptions for rare binary outcomes (discussed … choose to use exact methods but we don‘t
specifically recommend exact methods over fixed effect models discussed … As discussed
earlier, tests of statistical heterogeneity should not be the only consideration for the
-
effectivehealthcare.ahrq.gov/sites/default/files/methodsguide_conductingquantitativesynthesis.pdf
October 01, 2010 - None of the authors has a financial interest in any of the products discussed in this document. … Results
We first discussed considerations for deciding whether to combine studies, followed by
discussions … Therefore, we recommend
random effects models, with exceptions for rare binary outcomes (discussed … choose to use exact methods but we don‘t
specifically recommend exact methods over fixed effect models discussed … As discussed
earlier, tests of statistical heterogeneity should not be the only consideration for the
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-choosing-outcomes.ppt
June 01, 2012 - (Genetic and prognostic tests are discussed further in modules 11 and 12.)
Overview
Segal JB. … Genetic tests are then further discussed in module 11, while prognostic tests are further discussed in … Patient preference was not discussed. … The other categories of outcomes that were discussed are emotional, social, cognitive, and behavioral
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-bias_methods.pdf
February 01, 2013 - The methods used by the EPC program at this earlier stage are
discussed elsewhere.11 Likewise, we recognize … The two stages of assessment are discussed in more detail below. … gray literature documents for eligibility in the SR using the key
questions and inclusion criteria as discussed … EPC reviewers should have discussed and established a priori guidance on when to
include specific types … bias in study selection overlap
with considerations to reduce bias when defining the key questions (discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/multinational-registries-guide-3rd-ed-addendum-white-paper.pdf
February 01, 2018 - As discussed in later sections, inclusion of additional countries requires greater resources to
support … Patient-Reported Outcomes
As discussed in Chapter 5 of the User’s Guide, PROs are defined as “a measurement … Regulatory, Ethical, and Legal Considerations
In addition to the planning and design considerations discussed … challenges as other types of registries in the
implementation and operational phases; these challenges are discussed … Recruitment and Retention of Patients and Providers
As discussed in previous sections, recruitment
-
effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-choosing-outcomes.ppt
June 01, 2012 - (Genetic and prognostic tests are discussed further in modules 11 and 12.)
Overview
Segal JB. … Genetic tests are then further discussed in module 11, while prognostic tests are further discussed in … Patient preference was not discussed. … The other categories of outcomes that were discussed are emotional, social, cognitive, and behavioral